# Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study

> **NCT03619005** · PHASE3 · WITHDRAWN · sponsor: **EndoCeutics Inc.**

## Conditions studied

- Hypoactive Sexual Desire Disorder (HSDD)

## Interventions

- **DRUG:** Placebo Vaginal Insert
- **DRUG:** Prasterone 6.5 mg (0.50%) Vaginal Insert

## Key facts

- **NCT ID:** NCT03619005
- **Lead sponsor:** EndoCeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-11-13
- **Primary completion:** 2019-08-15
- **Final completion:** 2019-12-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business decision to not continue this study (only few subjects were screened).
- **Last updated:** 2020-07-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03619005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03619005, "Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03619005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*